Page 32 - GTM-2-3

Global Translational Medicine Critical roles for BRD4 identified in cancer

Proc Natl Acad Sci U S A, 108: 16669–16674. 74. Zhang P, Wang D, Zhao Y, et al., 2017, Intrinsic BET inhibitor
resistance in SPOP-mutated prostate cancer is mediated by
https://doi.org/10.1073/pnas.1108190108
BET protein stabilization and AKT-mTORC1 activation.
66. Ding D, Zheng R, Tian Y, et al., 2022, Retinoblastoma protein Nat Med, 23: 1055–1062.
as an intrinsic BRD4 inhibitor modulates small molecule
BET inhibitor sensitivity in cancer. Nat Commun, 13: 6311. https://doi.org/10.1038/nm.4379
75. Wang W, Tang Y, Xiao Q, et al., 2021, Stromal induction of
https://doi.org/10.1038/s41467-022-34024-y
BRD4 phosphorylation results in chromatin remodeling and
67. Weintraub SJ, Prater CA, Dean DC, 1992, Retinoblastoma BET inhibitor resistance in colorectal cancer. Nat Commun,
protein switches the E2F site from positive to negative 12: 4441.
element. Nature, 358: 259–261.
https://doi.org/10.1038/s41467-021-24687-4
https://doi.org/10.1038/358259a0
76. Garnier JM, Sharp PP, Burns CJ, 2014, BET bromodomain
68. Jin X, Ding D, Yan Y, et al., 2019, Phosphorylated RB inhibitors: A patent review. Expert Opin Ther Pat, 24: 185–
promotes cancer immunity by inhibiting NF-κB activation 199.
and PD-L1 expression. Mol Cell, 73: 22–35.e6.
https://doi.org/10.1517/13543776.2014.859244
https://doi.org/10.1016/j.molcel.2018.10.034
77. Rahman S, Sowa ME, Ottinger M, et al., 2011, The Brd4
69. Hassler M, Singh S, Yue WW, et al., 2007, Crystal structure extraterminal domain confers transcription activation
of the retinoblastoma protein N domain provides insight independent of pTEFb by recruiting multiple proteins,
into tumor suppression, ligand interaction, and holoprotein including NSD3. Mol Cell Biol, 31: 2641–2652.
architecture. Mol Cell, 28: 371–385.
https://doi.org/10.1128/MCB.01341
https://doi.org/10.1016/j.molcel.2007.08.023
78. Chaidos A, Caputo V, Gouvedenou K, et al., 2014, Potent
70. Liu, N, Ling R, Tang X, et al., 2022, Post-translational antimyeloma activity of the novel bromodomain inhibitors
modifications of BRD4: Therapeutic targets for tumor. Front I-BET151 and I-BET762. Blood, 123: 697–705.
Oncol, 12: 847701.
https://doi.org/10.1182/blood-2013-01-478420
https://doi.org/10.3389/fonc.2022.847701
79. Wyce A, Degenhardt Y, Bai Y, et al., 2013, Inhibition of BET
71. Dai X, Gan W, Li X, et al., 2017, Prostate cancer-associated bromodomain proteins as a therapeutic approach in prostate
SPOP mutations confer resistance to BET inhibitors through cancer. Oncotarget, 4: 2419–2429.
stabilization of BRD4. Nat Med, 23: 1063–1071.
https://doi.org/10.18632/oncotarget.1572
https://doi.org/10.1038/nm.4378
80. Riveiro ME, Astorgues-Xerri L, Vazquez R, et al., 2016,
72. Janouskova H, El Tekle G, Bellini E, et al., 2017, Opposing OTX015 (MK-8628), a novel BET inhibitor, exhibits
effects of cancer-type-specific SPOP mutants on BET antitumor activity in non-small cell and small cell lung
protein degradation and sensitivity to BET inhibitors. Nat cancer models harboring different oncogenic mutations.
Med, 23: 1046–1054. Oncotarget, 7: 84675–84687.
https://doi.org/10.1038/nm.4372 https://doi.org/10.18632/oncotarget.13181
73. Jin X, Yan Y, Wang D, et al., 2018, DUB3 promotes 81. Tontsch-Grunt U, Traexler PE, Baum A, et al., 2022,
BET inhibitor resistance and cancer progression by Therapeutic impact of BET inhibitor BI 894999 treatment:
deubiquitinating Brd4. Mol Cell, 71: 592–605.e4. Backtranslation from the clinic. Br J Cancer, 127: 577–586.
https://doi.org/10.1016/j.molcel.2018.06.036 https://doi.org/10.1038/s41416-022-01815-5

Volume 2 Issue 3 (2023) 11 https://doi.org/10.36922/gtm.1442